2019

August 19, 2019
Boston Scientific Closes Acquisition of BTG plc.

MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously...

August 15, 2019
Santé Canada accorde la licence d’instrument médical au système de cryoablation ICEfxMC de BTG Grâce à cette nouvelle technologie, les médecins canadiens ont une solution de rechange très peu invasive aux interventions de cryoablation tumorale actuelles

Ottawa, Canada, 15 August 2019 BTG International Canada Inc., filiale de la société BTG plc (BTG à la Bourse de Londres) spécialiste mondial en produits médicaux, a annoncé l’approbation...

August 15, 2019
BTG receives Health Canada Medical Device License for the ICEfx™ Cryoablation System

-- New technology provides physicians in Canada with a minimally invasive alternative to current tumour cryoablation procedures Ottawa, Canada -- BTG International Canada Inc., part of the global...

August 5, 2019
Randomized double-blinded study to commence on DigiFab® for kidney injury related to CABG surgery

Ottawa, Canada -- BTG plc (LSE: BTG), the global healthcare company, today announced the start of a randomized double-blinded clinical study, initiated by researchers at the University of Maryland...

July 23, 2019
Recommendations for personalised HCC treatment with Y90 TheraSphere™ published by an international multidisciplinary group

-- Supported by comparative Dosisphere data, a phase II multicentric randomised dosimetry trial London, UK -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus...

July 16, 2019
BTG to invest in Chinese medical isotope diagnosis and treatment company Chengdu New Radiomedicine Technology

BTG International Asia Limited, a subsidiary of BTG plc (LSE: BTG) announced today that it has agreed to invest RMB 76million (approximately USD 11million) in the Chinese medical isotope diagnosis...

July 11, 2019
NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®

BTG plc (LSE: BTG), the global healthcare company, today highlighted the first publication of National Comprehensive Cancer Network (NCCN) pediatric acute lymphoblastic leukemia (ALL) guidelines...

June 25 2019
Radioembolization treatment for primary liver cancer and metastatic liver cancer now available in Argentina

Argentina, 25 June 2019 Argentina now the second South American country to offer TheraSphere™ treatment for liver cancer patients June 25, 2019: BTG plc (LSE: BTG), a global healthcare company,...

June 25, 2019
Radioembolization treatment for primary liver cancer and metastatic liver cancer now available in Brazil

Brazil, 25 June 2019 Brazil to be the first South American country to offer TheraSphere® treatment for liver cancer patients June 25, 2019: – BTG plc (LSE: BTG), a global healthcare company,...

April 29, 2019
Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing

Bothell, WA, 29 April 2019 BTG plc (LSE: BTG), the global specialist healthcare company, today highlighted the VIEW VLU Registry interim study results, presented at the International Vein Congress...

April 29, 2019
Trial finds patients receiving CroFab® antivenom less likely to use opioids for pain control

Philadelphia, PA, 29 April 2019 BTG plc (LSE: BTG), the global healthcare company, today announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids...

April 18 2019
BTG plc: close period update

London, UK, 18 April 2019 BTG plc (LSE: BTG), the global healthcare company, provides the following update for the 12 months ended 31 March 2019. Trading performance Product Sales for the year are...

March 07 2019
BTG Crossing Devices are Highlighted at the CTO Summit in NY

Bothell, Washington, 07 March 2019 BTG plc (LSE: BTG), the global healthcare company, exhibited the BTG Crossing Devices portfolio at the Chronic Total Occlusion (CTO) Summit in New York City from...

March 05 2019
New research validates clinical value of treating Copperhead envenomation with CroFab®

Philadelphia, 05 March 2019 BTG plc (LSE: BTG), the global healthcare company, announced that research published today in PLOS ONE establishes the Patient-Specific Functional Scale (PSFS) as a...

February 14, 2019
A Retrospective Study of Medicare claim data shows patients treated with Voraxaze® had shorter hospitalizations and lower mortality

London, 14 February 2019 BTG plc (LSE: BTG), the global healthcare company, today announced the publication of data showing that cancer patients with presumed methotrexate toxicity treated with...

February 05 2019
NHS England expands loco-regional treatment options for colorectal cancer patients with metastatic disease.

London, UK, 05 February 2019 BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019, NHS...

January 08, 2019
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims

Philadelphia, 08 January 2019 BTG, the global healthcare company, is partnering with OMNY to improve visibility of inventory data for its antivenom product CroFab® using distributed ledger...

January 21 2019
Australian Patient Treated With DC Bead LUMI™, the first commercially available Radiopaque Drug-Eluting Bead

21 January 2019 BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development of the market...

Top